A Lumina–Gallup study finds 47% of students have seriously considered changing majors because of AI, while 57% use AI weekly and many campus policies remain unclear.

Eli Lilly will buy Boston‑based Centessa for about $6.3B, adding an orexin agonist program led by cleminorexton. The deal pays $38 per ADS up front and could reach $47 with milestones.

Indianapolis‑based Eli Lilly says retatrutide met a Phase‑3 diabetes endpoint with notable A1c and double‑digit weight drops at 40 weeks, while more safety and regulatory steps remain.

Gov. Mike Braun announced a $1 billion pledge to expand central Indiana’s life‑sciences and ag ecosystem, saying it could support as many as 100,000 jobs.

Sen. Todd Young says Indiana's new federal drone test‑site designation has manufacturers lining up to test tech and could spur manufacturing and biomanufacturing jobs.

IU researchers show that sampling the right water pools removes puzzling isotope mismatches and could sharpen drought and water‑use forecasts for crops and ecosystems.

Indiana Donor Network used an in‑house ex‑vivo lung perfusion system to rehabilitate lungs rejected elsewhere, enabling a transplant that saved a local man.

BOAH confirmed HPAI at a Boone County turkey farm affecting about 18,763 birds; control and surveillance zones are now in place and nearby farms will be tested.

DHS launched a website, 'Worst of the Worst,' for public search of removed criminal illegal aliens, praised by Rep. Michelle Davis for promoting safety and transparency.

Marian University study finds risky behaviors such as binge drinking and drug use prevalent among U.S. medical students, with calls for better mental health support.

Overdose Lifeline premiered a documentary for youth drug prevention at Phoenix Theatre Cultural Center, offering a realistic view on substance experimentation risks rather than just saying no.

Eli Lilly introduces discounted single-dose vials of its obesity drug Zepbound, aiming to improve affordability and access for patients without insurance.

Eli Lilly's drug tirzepatide, branded as Zepbound and Mounjaro, has shown a 94% reduction in the risk of type 2 diabetes development, and sustained weight loss in adults with pre-diabetes and obesity.